Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
Total Valuation
Annovis Bio has a market cap or net worth of $97.00M. The enterprise value is $25.46M.
Market Cap$97.00M
Enterprise Value$25.46M
Share Statistics
Annovis Bio has 26,502,890 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,502,890
Owned by Insiders15.22%
Owned by Institutions0.83%
Financial Efficiency
Annovis Bio’s return on equity (ROE) is -2.64K and return on invested capital (ROIC) is -265.76%.
Return on Equity (ROE)-2.64K
Return on Assets (ROA)-1.77K
Return on Invested Capital (ROIC)-265.76%
Return on Capital Employed (ROCE)-2.66
Revenue Per Employee0.00
Profits Per Employee-3.07B
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Annovis Bio is ―. Annovis Bio’s PEG ratio is >-0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio6.58
Price to Fair Value6.58
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Annovis Bio had revenue of 0.00 and earned -24.59M in profits. Earnings per share was -2.02K.
Revenue0.00
Gross Profit0.00
Operating Income-26.69M
Pretax Income-24.59M
Net Income-24.59M
EBITDA-26.69M
Earnings Per Share (EPS)-2.02K
Cash Flow
In the last 12 months, operating cash flow was -24.98M and capital expenditures -5.00, giving a free cash flow of -24.98M billion.
Operating Cash Flow-24.98M
Free Cash Flow-24.98M
Free Cash Flow per Share-0.94
Dividends & Yields
Annovis Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.35
52-Week Price Change-30.55%
50-Day Moving Average3.15
200-Day Moving Average2.43
Relative Strength Index (RSI)48.61
Average Volume (3m)2.92M
Important Dates
Annovis Bio upcoming earnings date is May 19, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Annovis Bio as a current ratio of 3.59, with Debt / Equity ratio of 0.00%
Current Ratio3.59
Quick Ratio3.59
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio-14.40
Taxes
In the past 12 months, Annovis Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Annovis Bio EV to EBITDA ratio is -2.23, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA-2.23
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Annovis Bio has $15.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of $15.29M billion.
Cash & Marketable Securities$15.29M
Total Debt$0.00
Net Cash$15.29M
Net Cash Per Share$0.58
Tangible Book Value Per Share$0.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Annovis Bio is $12.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.50
Price Target Upside241.53% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast62.84%